person · Reporting owner

Malley Thomas

Disclosed activity across 4 companies

Tapewire entity: 41320
SEC CIK: 0001403322

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BeOne Medicines Ltd.BGNE · Entity 2168	Director	June 15, 2023	June 20, 2023
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954	Director	May 29, 2026	June 02, 2026
Kura Oncology, Inc.KURA · Entity 4871	Director	June 04, 2026	June 04, 2026
Tempest Therapeutics, Inc.OVAS · Entity 7734	Director	June 13, 2017	July 05, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BeOne Medicines Ltd.

Report date June 15, 2023 · Filed June 20, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	46,696	Reported balance After 2023-06-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-06-15 · Grant · Acquired 12,922 · Balance 46,696 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.41 · Expires 2033-06-14	Direct	26,975	Reported balance After 2023-06-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-15 · Grant · Acquired 26,975 · Balance 26,975 F3: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.
American Depositary SharesSEC Table I · non-derivative	Direct	30,000	Reported balance Holding disclosure · report date 2023-06-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30,000 F2: Each American Depositary Share represents 13 ordinary shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.

F2: Each American Depositary Share represents 13 ordinary shares.

F3: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F4: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Kiniksa Pharmaceuticals International, plc

Report date May 29, 2026 · Filed June 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	15,345	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Exercise / conversion · Acquired 2,799 · Balance 15,345 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.38 · Expires 2036-05-28	Direct	12,158	Reported balance After 2026-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-29 · Grant · Acquired 12,158 · Balance 12,158 F3: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	2,026	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Grant · Acquired 2,026 · Balance 2,026 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-29 · Exercise / conversion · Disposed 2,799 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee footnote	71,967	Reported balance Holding disclosure · report date 2026-05-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 71,967 F2: Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2: Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.

F3: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F4: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

F5: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Kura Oncology, Inc.

Report date June 04, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03	Direct	35,000	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in full on the one year anniversary of the date of grant.

Tempest Therapeutics, Inc.

Report date June 13, 2017 · Filed July 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	204,981	Reported balance After 2017-06-13 transaction · row 1 1 source row Row 1 · 2017-06-13 · Grant · Acquired 7,873 · Balance 204,981 F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2021 Filed Jun 21, 2021 20:37 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantOrdinary Shares	7,800	$0.00	$0.00	Disclosure SEC source: 0001651308-21-000121 · wf-form4_162430781053430.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,082 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document
June 30, 2020 Filed Jul 2, 2020 20:12 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	18,760	$0.00 Strike: $25.48	$0.00	Disclosure SEC source: 0001104659-20-080549 · a4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2030-06-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:08 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	23,000	$0.00 Strike: $17.97	$0.00	Disclosure SEC source: 0001209191-20-039070 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 17, 2020 Filed Jun 19, 2020 20:17 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	45,383	$0.00 Strike: $13.42	$0.00	Disclosure SEC source: 0001651308-20-000078 · wf-form4_159259781429439.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document
June 25, 2019 Filed Jun 27, 2019 20:07 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	13,000	$0.00 Strike: $19.55	$0.00	Disclosure SEC source: 0001209191-19-039242 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:07 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	64,610	$0.00 Strike: $9.23	$0.00	Disclosure SEC source: 0001651308-19-000054 · wf-form4_155993800860144.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document
May 29, 2019 Filed May 30, 2019 22:33 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	GrantShare Option · Derivative	18,760	$0.00 Strike: $15.47	$0.00	Disclosure SEC source: 0001179110-19-006868 · edgar.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2029-05-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019. Read SEC document
June 07, 2018 Filed Jun 8, 2018 20:10 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	13,000	$0.00 Strike: $16.35	$0.00	Disclosure SEC source: 0001209191-18-036661 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:50 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	17,442	$0.00 Strike: $16.15	$0.00	Disclosure SEC source: 0001104659-18-039246 · a4.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,442 Underlying: Ordinary Shares · 17,442 shares Expires 2028-06-05 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F3 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F3 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:50 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantOrdinary Shares	9,290	$0.00	$0.00	Disclosure SEC source: 0001104659-18-039246 · a4.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,290 F1 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document
May 29, 2018 Filed May 29, 2018 23:19 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	ConversionSeries B Preferred Shares · Derivative	71,967	$0.00	$0.00	Disclosure SEC source: 0001104659-18-036486 · a4.xml · derivative · entry 2 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Shares · 71,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · ownership.nature: Mr. Malley is the president of Mossrock Capital, LLC ("Mossrock") and may be deemed to beneficially own the shares owned by Mossrock. Read SEC document
May 29, 2018 Filed May 29, 2018 23:19 UTC	Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954	ConversionClass A Common Shares	71,967	$0.00	$0.00	Disclosure SEC source: 0001104659-18-036486 · a4.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 71,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Mr. Malley is the president of Mossrock Capital, LLC ("Mossrock") and may be deemed to beneficially own the shares owned by Mossrock. Read SEC document
June 13, 2017 Filed Jul 5, 2017 23:11 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	7,873	$0.00	$0.00	Disclosure SEC source: 0001179110-17-010097 · edgar.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,981 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
June 09, 2017 Filed Jun 12, 2017 21:52 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	10,000	$0.00 Strike: $8.60	$0.00	Disclosure SEC source: 0001209191-17-039261 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 02, 2017 Filed Jun 6, 2017 20:18 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	169,988	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0001179110-17-008657 · edgar.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,988 Underlying: Ordinary Shares · 169,988 shares Expires 2027-06-01 F1 · derivative.exercise_price: In ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: In ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. F1 · derivative.underlying_shares: In ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · balance_after: In ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. Read SEC document
March 31, 2017 Filed Apr 5, 2017 01:02 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	7,085	$0.00	$0.00	Disclosure SEC source: 0001179110-17-005740 · edgar.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,108 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
December 30, 2016 Filed Jan 5, 2017 01:30 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	8,660	$1.53	$13,249.80	Disclosure SEC source: 0001179110-17-000420 · edgar.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,023 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
November 23, 2016 Filed Nov 28, 2016 21:02 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	PurchaseAmerican Depositary Shares	30,000	$32.00	$960,000.00	Disclosure SEC source: 0001179110-16-032122 · edgar.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The purchase transaction reported on this Form 4 was effected as part of an underwritten public offering of Ordinary Shares in the form of American Depositary Shares of the Company. Read SEC document
September 30, 2016 Filed Oct 4, 2016 21:11 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	1,850	$0.00	$0.00	Disclosure SEC source: 0001179110-16-030317 · edgar.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,363 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.